Rankings / Hormones & Endocrine
Cabergoline
Hormones & Endocrine · Dopamine D2 agonist
Tier B
Bottom line
Read Off Label grades Cabergoline as B (6.8/10) based on strong evidence, strong benefit magnitude, and a med-risk safety profile.
Valvulopathy risk is real and dose-dependent — chronic Parkinson's-level dosing (3+ mg/day) is clearly associated; prolactinoma doses less certain.
Studied, labeled, or reported-use context: 0. — Rx; not individualized guidance.
What the evidence says
Valvulopathy risk is real and dose-dependent — chronic Parkinson's-level dosing (3+ mg/day) is clearly associated; prolactinoma doses less certain. Biohacker microdoses (0.25 mg weekly) are much lower than valvulopathy-risk dosing but long-term safety data in that population doesn't exist. Echocardiographic monitoring is described in some product-label and specialty-guideline contexts, with practices varying by dose, indication, duration, and jurisdiction.
Mechanism
Ergot-derived long-acting D2 dopamine receptor agonist; suppresses prolactin; used medically for hyperprolactinemia, prolactinoma, Parkinson's; off-label for post-orgasmic refractory reduction
Studied, labeled, or reported dose & route
0.25-0.5 mg once weekly (low-dose biohacker); 0.25-1 mg 2x/week (hyperprolactinemia)
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Cabergoline's effects?
- Read Off Label rates the evidence for Cabergoline as Strong and the benefit magnitude as strong, producing an overall grade of B (6.8/10). Valvulopathy risk is real and dose-dependent — chronic Parkinson's-level dosing (3+ mg/day) is clearly associated; prolactinoma doses less certain.
- What safety findings are reported for Cabergoline?
- Cabergoline has a med risk profile in the database. Med (cardiac valvulopathy with high chronic doses — well-documented in Parkinson's and pituitary dosing; nausea; orthostatic hypotension; compulsive behaviors) Legal status: Rx (Dostinex).
- What doses or routes are reported for Cabergoline?
- 0.25-0.5 mg once weekly (low-dose biohacker); 0.25-1 mg 2x/week (hyperprolactinemia) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Cabergoline work?
- Ergot-derived long-acting D2 dopamine receptor agonist; suppresses prolactin; used medically for hyperprolactinemia, prolactinoma, Parkinson's; off-label for post-orgasmic refractory reduction
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.